This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Back to overview
Opdam, Mark.jpg

Mark Opdam, BSc



I perform most immunostaining for tumors and tissues of interest for the Linn lab. In addition, I contribute to a multitude of projects including the MATADOR trial (ISRCTN61893718).

The aim of this project is to assess whether we can use gene expression profiling to determine the most effective adjuvant chemotherapy for breast cancer patients. In addition, pharmacogenomic analyses will be carried out in this project to correlate chemotherapy toxicity and efficacy with patients' genotypes. The ultimate goal is to contribute knowledge that can be used to individualize therapy.